Pregabalin vs placebo at end of treatment: Dizziness
- Population
- patients with fibromyalgia
- Intervention
- Pregabalin
- Comparison
- placebo at end of treatment
- Outcome
- Dizziness
Pregabalin leads to higher dizziness reported to be an adverse event compared with placebo at end of treatment (high certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Pregabalin vs placebo at end of treatment Dizziness reported to be an adverse event · People with fibromyalgia Pregabalin leads to higher dizziness reported to be an adverse event compared with placebo at end of treatment (high certainty). Anticonvulsants for fibromyalgia (2013) · Cochrane Headline outcomes only | RR 3.77 [3.06, 4.63] | 5 studies · 3257 participants | High |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Pregabalin vs placebo · people with drug‐resistant focal epilepsy · 1 review
- Pregabalin vs active comparators · people with drug‐resistant focal epilepsy · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.